Search the Newsreel

Q2 2026 Cineplex Inc Earnings Call Transcript

EPL Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Earnings Flash (CGX.TO) Cineplex Inc. Reports Q2 Revenue C$383.7M, vs. FactSet Est of C$378.7M

Replimune Prices $150 Million Underwritten Offering

(RTTNews) - Replimune Group, Inc. (REPL), a commercial-stage biotechnology company developing oncolytic immunotherapies, announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at $12.06 per share. In addition, the company is issuing pre-funded warrants, equal to the offering price …

Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages

Repligen Corporation (NASDAQ:RGEN) has received a "Moderate Buy" consensus rating from eighteen brokerages, with an average 12-month price target of $166.43. The company recently surpassed quarterly earnings and revenue expectations, reporting $0.54 EPS and $204.13 million in revenue, an 11.9% year-over-year increase. Despite a …

ePlus (NASDAQ: PLUS) trust schedules sale of 1,000 shares from stock awards

The Darren S. Raiguel Trust, associated with ePlus (NASDAQ: PLUS), has filed to sell 1,000 shares of common stock through Rockefeller Capital Management. The aggregate market value of these shares is $90,768.80 as of August 10, 2026, and they are related to stock awards …

Repligen Shares Surge 16.2% as Record Revenue Offsets Shrinking Q2 Margins

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding its …

Replimune Group stock hits 52-week high at 13.92 USD

Replimune Group stock has reached a 52-week high of $13.92, driven by a 128% one-year return and recent FDA accelerated approval for its cancer treatment TUDRIQEV. While analysts have upgraded the stock and increased price targets, InvestingPro suggests the shares may be overvalued, and …

Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months

Replimune Group's stock has surged nearly 223% in the past three months, primarily due to the FDA's accelerated approval of its lead oncolytic immunotherapy, RP1 (Tudriqev), for advanced melanoma. This approval, in combination with Bristol Myers' Opdivo, marks a significant commercial milestone for Replimune …

Replimune prices $150M underwritten offering of common stock and pre-funded warrants

Replimune (REPL) has priced an underwritten offering to raise approximately $150.0 million in gross proceeds. The offering includes 9,701,490 shares of common stock and pre-funded warrants for 2,736,340 shares, priced at $12.06 per share. Net proceeds are estimated to be around $140.5 million after …

Repligen Corporation (RGEN) Stock Analysis: A Healthcare Standout with 13.3% Potential Upside

Repligen Corporation (RGEN) is analyzed as a strong player in the healthcare sector, specifically medical instruments and supplies, with a current market cap of $9.25 billion and a potential upside of 13.3% according to analysts. The company shows promising revenue growth, positive analyst sentiment …

Repligen (RGEN) Is Up 16.2% After Revenue Rises But Profitability Compresses In Q2 2026

In July 2026, Repligen Corporation reported second-quarter 2026 results showing revenue of US$204.13 million versus US$182.37 million a year earlier, while net income fell to US$5.01 million from US$14.87 million and diluted EPS from continuing operations decreased to US$0.09 from US$0.26. Over the six-month …

Repligen (RGEN) Could Be 10% Below Fair Value On Mixed Q2 Earnings

Repligen (RGEN) recently reported mixed Q2 2026 earnings, showing higher revenue but lower net income and EPS year-over-year. Despite this, the stock has seen strong recent momentum, with a 90-day return of 41.4% and a 1-year return of 47.09%, positioning it about 10% below …

Replimune in the spotlight: Earnings loom days after FDA approval

Replimune Group Inc. is set to report its fiscal fourth-quarter earnings, marking its first financial update since receiving FDA approval for its melanoma therapy, Tudriqev. Despite the regulatory success, analysts have significantly lowered EPS estimates, though most still rate the stock a "Buy" with …

Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment

The FDA has granted accelerated approval to Replimune Group Inc. for its novel oncolytic immunotherapy, Tudriqev, for advanced cutaneous melanoma. This approval comes after previous rejections and relies on promising clinical trial results from the IGNYTE trial, which showed a 24.2% objective response rate …

Is Repligen’s (RGEN) Rising Revenue But Softer Earnings Rewriting Its Profitability Story?

Repligen Corporation (RGEN) reported rising revenue in Q2 2026, reaching US$204.13 million, but net income and earnings per share fell compared to the previous year. This performance highlights a conflict between increased demand and pressure on profitability due to the company's cost structure and …

Law Offices of Frank R. Cruz Encourages Replimune Group, Inc. (REPL) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz has filed a class action lawsuit against Replimune Group, Inc. (REPL) on behalf of shareholders who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made materially false and misleading statements …

There's A Lot To Like About Seplat Energy's (LON:SEPL) Upcoming US$0.12 Dividend

Sei Investments Co. Has $3.72 Million Stock Holdings in ePlus inc. $PLUS

Sei Investments Co. significantly increased its stake in ePlus inc. (NASDAQ:PLUS) by 180.9% in the first quarter, now holding 49,448 shares valued at $3.72 million. This comes as ePlus reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and declared a …

Replimune Group Inc (REPL) Earnings Forecast: Future EPS & Revenue Growth Estimates

River Road Asset Management (NASDAQ: PLUS) reports 4.5% stake in ePlus

River Road Asset Management, LLC has reported a 4.5% beneficial ownership stake in ePlus Inc. (NASDAQ: PLUS), totaling 1,162,635 shares of common stock. This filing, a SCHEDULE 13G/A, indicates that River Road holds sole voting power over 986,219 shares and sole dispositive power over …

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market. Continue Reading

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (REPL)

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise …

REPL INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) …

Replimune Group Inc (REPL) Stock News Today

Darren Raiguel Sells 200 Shares of ePlus (NASDAQ:PLUS) Stock

ePlus COO Darren Raiguel sold 200 shares of the company's stock for $19,600, retaining 69,036 shares valued at approximately $6.77 million. The company reported strong quarterly earnings of $1.28 per share, exceeding analyst expectations, and declared a quarterly dividend of $0.27 per share. Institutional …

Seplat Energy (LSE:SEPL) Brings Security And Supply Into The UK Energy Stocks Debate

Replimune Wins FDA Accelerated Nod For TUDRIQEVTM In Advanced Melanoma

(RTTNews) - Replimune Group, Inc. (REPL) announced that the U.S. FDA has granted accelerated approval for TUDRIQEVTM, in combination with Nivolumab (Bristol Myers Squibb), for adults with unresectable advanced cutaneous melanoma who have progressed following anti-PD-1 antibody-based therapy. Advanced melanoma patients often face limited …

Stockholder Alert: Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action

Robbins LLP has filed a class action lawsuit against Replimune Group, Inc. on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune misled investors regarding the efficacy of its lead product candidate, RP1, particularly …

Replimune Group, Inc. (REPL) Stock Price, News, Quote & History

This article provides comprehensive information on Replimune Group, Inc. (REPL), a clinical-stage biotechnology company focused on cancer immunotherapies. It includes current stock price, historical performance data, financial overview, analyst insights, and comparisons with similar companies. The stock showed an 8.71% increase at close on …

Replimune gains accelerated approval of Tudriqev for cutaneous melanoma

[Dermoscopic image of malignant melanoma skin tumor] Izzet Esmece/iStock via Getty Images * The US FDA has granted accelerated approval to Replimune's (REPL [https://seekingalpha.com/symbol/REPL]) gene therapy Tudriqev (vusolimogene oderparepvec) in combination with Bristol Myers Squibb's (BMY [https://seekingalpha.com/symbol/BMY]) Opdivo (nivolumab) as a second-line treatment for …

Replimune Group (REPL): Montanova-affiliated investors report over 7% ownership

Montanova Capital, LLC and affiliated investors, including Aaron Cowen, have reported a significant ownership stake in Replimune Group, Inc. (REPL) via a Schedule 13G/A filing. Montanova Capital and Aaron Cowen each beneficially own 7.9% of Replimune's common stock, while Averill Master Fund, Ltd. holds …

EPLUS Inc (PLUS) COO sells 200 shares via 10b5-1 trading plan

EPLUS Inc.'s Chief Operating Officer, Darren S. Raiguel, reported selling 200 shares of common stock at $98 per share on August 4, 2026. The transaction was carried out through a revocable trust under a pre-arranged Rule 10b5-1 trading plan established in November 2025. Following …

FDA Approves Replimune’s Melanoma Drug on Third Attempt

The FDA has approved Replimune Group's melanoma drug, Tudriqev, after two prior rejections due to clinical data quality concerns. Tudriqev is a genetically modified virus injected into tumors to kill cancer cells and activate an immune response. This approval marks the end of a …

US FDA approves Replimune's skin cancer drug after prior rejections

The U.S. FDA has approved Replimune's drug Tudriqev, in combination with Bristol Myers Squibb's Opdivo, for a difficult-to-treat form of advanced melanoma. This approval marks Replimune's first marketed product after previous rejections, and the drug will compete with Iovance Biotherapeutics' Amtagvi. The decision was …